Is It Safe to Take Abiraterone With Spironolactone and Hydrochlorothiazide?

No. Taking abiraterone together with a combination product containing spironolactone and hydrochlorothiazide is classified as contraindicated—meaning the combination is not recommended and should generally be avoided. According to the source record, spironolactone binds to the androgen receptor and may increase PSA levels when used with abiraterone, which creates a clinical conflict in patients being treated for prostate cancer.

What the Source Says

The documented interaction record classifies this pair as contraindicated with the following specifics:

• Severity: Contraindicated (the highest level of concern requiring avoidance)
• Description: Spironolactone binds to androgen receptor and may increase PSA levels; concomitant use is not recommended.
• Mechanism: Androgen receptor binding
• Source: NLP-derived from spironolactone and hydrochlorothiazide labeling
• Last Updated: May 4, 2026

This record reflects official drug-labeling guidance and means that using these medications together requires careful reassessment of clinical need and, in most cases, selection of an alternative medication.

How to Understand This Interaction

To make sense of this interaction, it helps to know what each medication does and why they conflict:

What Is Abiraterone?

Abiraterone is a hormone therapy used to treat certain types of prostate cancer. It works by blocking the enzyme 17α-hydroxylase/17,20-lyase (CYP17A1), which is involved in androgen (male hormone) production. By reducing androgen levels in the body, abiraterone helps slow or stop the growth of androgen-dependent prostate cancer cells. Treatment success is typically monitored by tracking prostate-specific antigen (PSA) levels—a marker in the blood that reflects prostate cancer activity. Lower PSA levels generally indicate that the cancer is responding to treatment.

What Are Spironolactone and Hydrochlorothiazide?

Spironolactone and hydrochlorothiazide are diuretic (water-removing) medications used together to manage high blood pressure and fluid retention. Hydrochlorothiazide is a thiazide diuretic that works by increasing urine output. Spironolactone is a potassium-sparing diuretic that blocks aldosterone, a hormone that regulates fluid and salt balance. The combination is often prescribed because hydrochlorothiazide can cause potassium loss, while spironolactone helps retain potassium, balancing each other's effects.

Why Do They Conflict?

The problem stems from spironolactone's structure and behavior. Spironolactone is a steroid-based compound that binds to the androgen receptor—the same receptor that abiraterone is working to block. When spironolactone binds to the androgen receptor, it can act as a partial agonist (a weak activator) of that receptor. In patients taking abiraterone for prostate cancer, this may result in increased PSA levels, counteracting the cancer-fighting effect of abiraterone therapy and potentially confounding the assessment of whether the cancer is responding to treatment.

In simpler terms: abiraterone is trying to "turn off" androgen signaling to slow prostate cancer growth. Spironolactone's ability to engage the androgen receptor may "turn it back on" to some degree, working against abiraterone's intended effect. That is why the combination is not recommended.

Distinction Between Documented Mechanism and General Background

The source record specifies that the mechanism of this interaction is androgen receptor binding. This is a direct, documented mechanism. The general pharmacology of how androgen receptor signaling relates to prostate cancer is well-established medical science, but the specific clinical impact of combining these two drugs in individual patients can vary and requires physician and pharmacist oversight.

Who Should Pay Particular Attention

This interaction is especially relevant for:

• Patients with prostate cancer taking abiraterone: If you are on abiraterone therapy, inform your healthcare provider immediately if you are taking or considering spironolactone-hydrochlorothiazide for blood pressure or fluid management.
• Patients with both prostate cancer and hypertension or heart disease: Managing multiple conditions can create medication conflicts. Your doctor may need to select an alternative blood-pressure medication.
• Patients whose PSA levels are being monitored: Because this interaction may affect PSA readings, any increase in PSA during concurrent use could be misinterpreted as cancer progression rather than a medication effect.

It is also important to note that this interaction applies to the combination product of spironolactone and hydrochlorothiazide. If you are taking these medications separately, or if your blood-pressure regimen uses only hydrochlorothiazide without spironolactone, the risk profile may be different and should be discussed with your pharmacist or physician.

Hypothetical Examples

Hypothetical Scenario 1: Cancer Monitoring Confusion

Imagine a patient with metastatic prostate cancer who is stable on abiraterone therapy with declining PSA levels over six months. His physician adds a spironolactone-hydrochlorothiazide combination to manage newly diagnosed hypertension. Three months later, his PSA level rises unexpectedly during routine blood work. Without awareness of the potential interaction, the clinical team might interpret this rise as disease progression requiring a change in cancer strategy. However, the rise could partly reflect the androgen-receptor activity from spironolactone rather than true cancer recurrence. This underscores why avoiding the combination prevents diagnostic confusion and unnecessary treatment changes.

Hypothetical Scenario 2: Medication Substitution

A patient starting abiraterone for prostate cancer is already taking spironolactone-hydrochlorothiazide for blood pressure control. Before beginning abiraterone therapy, a careful medication review flags this conflict. The healthcare team discusses alternative blood-pressure medications with the patient—such as a different class of diuretic, an ACE inhibitor, or an angiotensin-receptor blocker—that do not interact with abiraterone. By making the switch beforehand, the patient can begin abiraterone therapy with confidence that PSA monitoring will reflect only the drug's therapeutic effect, not interference from a competing medication.

What to Discuss With a Pharmacist or Physician

If you are taking or considering both abiraterone and spironolactone-hydrochlorothiazide, bring the following points to your next appointment:

• "I take (or am prescribed) both abiraterone and spironolactone-hydrochlorothiazide. Is this combination safe for me?" — This opens the conversation directly and ensures your care team is aware of both medications.
• "Are there alternative blood-pressure or diuretic medications I could take instead of the spironolactone-hydrochlorothiazide combination?" — Your physician may recommend a substitute that does not conflict with abiraterone, such as a loop diuretic, a different class of blood-pressure drug, or monotherapy with hydrochlorothiazide alone (if spironolactone is the specific concern).
• "How will this interaction affect my PSA monitoring?" — If you have already been on both medications, ask whether your PSA trends may have been affected and whether your cancer-treatment plan needs reassessment.
• "What signs or symptoms should I watch for if I continue both medications temporarily?" — Your healthcare provider may advise specific monitoring if an immediate switch is not possible, though avoidance is the preferred approach.
• "When should we review my blood-pressure regimen after starting abiraterone?" — If abiraterone is new, establishing a timeline for medication review ensures that any necessary adjustments to your blood-pressure treatment happen promptly.

Important: Do not stop, skip, or change any of your medications on your own. All decisions about medication changes must be made in consultation with your physician or pharmacist, who understands your full medical history, cancer stage, and other conditions.

Key Takeaways

• Abiraterone and spironolactone-hydrochlorothiazide are classified as a contraindicated drug pair, meaning the combination is not recommended and should generally be avoided.
• Spironolactone binds to the androgen receptor, which may increase PSA levels and interfere with the cancer-fighting effect of abiraterone therapy.
• This interaction is particularly important for patients with prostate cancer whose treatment response is monitored by PSA levels.
• Alternative blood-pressure and diuretic medications are available and should be discussed with your healthcare provider if you require both abiraterone and blood-pressure management.
• Any decision to continue, modify, or stop medications must be made with your physician or pharmacist, never on your own.

Sources

• FDA Open Data — Primary source for drug labeling and interaction warnings
• DailyMed (National Library of Medicine) — Official drug labeling and FDA-approved prescribing information
• RxNorm (National Library of Medicine) — Standardized drug naming and relationship data
• PubMed (National Institutes of Health) — Peer-reviewed medical literature on prostate cancer treatment and drug interactions

Take Action: Check Your Medications

If you are taking abiraterone and spironolactone-hydrochlorothiazide or any combination of medications for prostate cancer and blood pressure, visit checkdruginteractions.com to run a complete interaction check on your medication list. Enter all the drugs, supplements, and over-the-counter products you take to identify potential conflicts before they cause harm. Then schedule a conversation with your pharmacist or physician to review any flagged interactions and confirm that your current regimen is safe and appropriate for your health goals. Your healthcare team is your best resource for personalized medication guidance.